BIOCRYST PHARMACEUTICALS INC

Biocryst’s BCRX slump: Why the biotech stock’s 2.4% drop signals deeper valuation and pipeline doubts, and what investors should watch next.

Biocryst (BCRX) edges 1.6% lower on Oct 21, 2026 amid a mixed peer landscape; biotech investors weigh its rare‑disease pipeline and 200‑day trend for insight.